Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 95 clinical trials
Featured trial
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

platelets, which increases risk of bleeding. Myelofibrosis often causes an enlarged spleen. The purpose of this study is to see if a combination of navitoclax and ruxolitinib is more effective and safe in

  • 105 views
  • 29 Apr, 2021
  • 149 locations
Featured trial
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

this study is to assess safety and change in spleen volume when navitoclax is given in combination with ruxolitinib, as compared to best available therapy, for adult participants with MF.

  • 252 views
  • 29 Apr, 2021
  • 225 locations
Featured trial
A Study Evaluating Safety and Tolerability and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

safety, tolerability, and pharmacokinetics (PK) of navitoclax when administered alone (Part 1) or when administered in combination with ruxolitinib (Part 2). In Part 2, participants must have been

bone marrow procedure
polycythemia
ruxolitinib
myelofibrosis
stem cell transplantation
  • 1 views
  • 01 Sep, 2021
  • 37 locations
Featured trial
Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

People with Myelofibrosis are asked to participate in a research study being conducted by Montefiore Medical Center.

  • 0 views
  • 06 Aug, 2021
  • 1 location
Featured trial
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in subjects with myelofibrosis.  

myeloproliferative disorders
leukemia
myelofibrosis
  • 163 views
  • 25 Aug, 2021
  • 9 locations
Featured trial
INCB 18424-304: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE-AD2) for 304

A Phase 3, randomized (2:2:1), double-blind, 8-week vehicle control efficacy and safety study of ruxolitinib followed by a randomized, double-blind, 44-week long term safety (LTS) extension period

atopic dermatitis
atopic dermatitis/eczema
eczema
dermatitis
  • 379 views
  • 25 Aug, 2021
  • 11 locations
Featured trial
INCB 18424-303: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE-AD1)

A Phase 3, randomized (2:2:1), double-blind, 8-week vehicle control efficacy and safety study of ruxolitinib followed by a randomized, double-blind, 44-week long term safety (LTS) extension period

atopic dermatitis
eczema
atopic dermatitis/eczema
  • 248 views
  • 25 Aug, 2021
  • 19 locations
Featured trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

myeloproliferative disorder
myelofibrosis
myeloproliferative syndromes
myeloproliferative disorders
myeloproliferative/myelodysplastic disorders
  • 0 views
  • 25 Aug, 2021
  • 7 locations
Featured trial
A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Versus-Host Disease

A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Versus-Host Disease

stem cell transplant
bone marrow transplant
transplant conditioning
stem cell transplantation
nutritional supplement
  • 305 views
  • 08 Dec, 2020
  • 1 location
Featured trial
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. INCB000928 tablets will be administered orally at a starting dose of 50 mg QD in

anemia
  • 67 views
  • 25 Aug, 2021
  • 4 locations